newsfilter
← Earnings
Earnings Releases·

Entrada Therapeutics — Third Quarter 2026 Earnings Summary

  • Collaboration revenue declined to $0.9 million from $1.6 million year-over-year, while net loss improved to $39.7 million from $44.1 million as R&D and G&A expenses decreased.
  • Cash and marketable securities totaled $193.0 million as of September 30, 2026, down from $295.7 million at year-end 2025, with a projected cash runway extending into Q4 2027.
  • Clinical progress includes completion of open-label dosing for ELEVATE-44-201 Cohort 1 with data expected by year-end 2026, and ELEVATE-45-201 Cohort 1 data reported in October 2026 meeting primary safety objectives.
  • Strategic pipeline expansion features the nomination of ENTR-801 for Usher syndrome type 2A and the FDA grant of orphan drug designation for ENTR-601-45 in October 2026.
  • Four clinical data readouts are anticipated through the first half of 2027, including interim results from Vertex's GALILEO study for myotonic dystrophy type 1 in the second half of 2026.
Company
ENTRADA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology